(HealthDay News) — An experimental three-in-one blood pressure pill works better than layering on meds one at a time, a new clinical trial shows.
After a month on the combo pill, 81 percent of patients had their blood pressure under control compared with 55% of patients receiving standard care, researchers report.
“The triple pill still produced clinically meaningful reductions in blood pressure compared to standard care, even when standard care closely followed current guidelines and involved more clinic visits,” said lead investigator Dr. Dike Ojji, head of the Cardiovascular Research Unit at the University of Abuja in Nigeria.
“In low-income countries, fewer than one in four treated people achieve blood pressure control, and in high-income settings it is only between 50 percent and 70 percent, so to see rates of over 80 percent in just one month is impressive,” Ojji added.
The GMRx2 pill, which was developed by the pharmaceutical company George Medicines, contains the blood pressure meds telmisartan, amlodipine and indapamide. It’s taken once daily. The company is part of the George Institute for Global Health.
Researchers compared people taking the combo pill to those receiving standard treatment for high blood pressure, which involves starting off with one drug and then adding on others.
Systolic blood pressure was 31 points lower in the combo pill group after six months of treatment, compared to 26 points lower with standard care, results showed.
The five-point systolic difference is equal to a 10 percent reduction in stroke, heart attack and heart failure risk between the two groups, researchers said in a George Institute news release.
It’s estimated more than a billion people worldwide have high blood pressure, which accounts for nearly 11 million deaths each year, researchers said in background notes.
George Medicines has submitted the combo drug to the U.S. Food and Drug Administration for approval.
The trial results were presented Saturday at the European Society of Cardiology’s annual meeting in London and published simultaneously in the Journal of the American Medical Association. Positive data from two other trials of the combo pill were also presented at the meeting.
The GMRx2 pill, developed by George Medicines, combines three proven blood pressure medications: telmisartan, amlodipine, and indapamide. This unique formulation offers a convenient, once-daily option for patients with high blood pressure.
In the clinical trial, patients taking GMRx2 experienced a more substantial reduction in systolic blood pressure compared to those receiving standard care. This improvement translates into a significant decrease in the risk of stroke, heart attack, and heart failure.
Black patients face a higher risk of developing high blood pressure and its associated complications, such as heart disease and stroke. This disparity is largely due to a complex interplay of genetic, environmental, and socioeconomic factors.
The availability of a highly effective treatment like GMRx2 could be a game-changer for Black patients. By providing a more efficient and effective way to manage high blood pressure, this medication could help reduce health disparities and improve outcomes.
High blood pressure is a major public health problem worldwide, affecting over a billion people. It is a leading cause of death and disability, contributing to millions of deaths each year.
The GMRx2 pill offers hope for improving blood pressure control and reducing the burden of this disease. By simplifying treatment regimens and increasing the likelihood of achieving blood pressure goals, this medication could have a serious impact on global health.
More information
The American Heart Association has more on managing high blood pressure.
SOURCE: George Institute for Global Health, news release, Aug. 31, 2024
By subscribing, you consent to receive emails from BlackDoctor.com. You may unsubscribe at any time. Privacy Policy & Terms of Service.
